News

The two designer cancer drugs appear to perform dramatically differently in a laboratory test comparing their ability to shut down a mutant, overactive growth signal in lung cancer

Conclusion of the transaction is now expected to occur in the third quarter of this year, subject to satisfaction of customary closing conditions, including regulatory approvals. Vicuron has

New studies in cell lines suggest that the combination, which targets a common gene pathway in colon cancer cells, could be more potent than either drug alone, and

The investigators from the University of Minnesota hope that by finding ways to increase the concentration of this regulator they may one day find a treatment for diabetes

The company is developing its “Tissue Repair Cells” for use in multiple medical indications, and has already received a phase I grant from the National Institute of Arthritis

Scientists have demonstrated that the loss of the p63 mouse gene, of which similar versions are present in many organisms, reduces the life expectancy of the rodents. Mice

The partnership now expects to commence a phase II clinical study with Moli1901 in dry eye syndrome. The companies said that they would share development and supply responsibilities

Under terms of the agreement, UCB and ImClone Systems will equally share the development costs for the drug, known as CDP-791, as well as worldwide profits derived from

Antibody optimization technologies assist drug companies in developing medicines with improved properties such as greater and longer lasting efficacy. Bioren has developed technologies called Walk-Through Mutagenesis (WTM) and